SCHEMBL10247214

SCHEMBL10247214

CNCCC(=O)NC1CCc2ccc(C(=O)NO)cc2C1

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 18/20 0.56
HDAC6 Q9UBN7 6/20 0.55
MTNR1A P48039 1/20 0.50
MTNR1B P49286 1/20 0.50
SMYD3 Q9H7B4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10247367 0.88 HDAC8 (0.58) HDAC8HDAC6MTNR1AMTNR1B
SCHEMBL10247193 0.83 HDAC8 (0.57) HDAC8HDAC6
SCHEMBL354112 0.79 HDAC8 (0.60) HDAC8HDAC6
SCHEMBL355453 0.79 HDAC8 (0.60) HDAC8HDAC6
SCHEMBL10253556 0.78 MTNR1A (0.61) HDAC8HDAC6MTNR1AMTNR1B
SCHEMBL10252714 0.76 HDAC8 (0.48) HDAC8HDAC6
SCHEMBL10247178 0.75 HDAC8 (0.48) HDAC8HDAC6
SCHEMBL10247052 0.75 HDAC8 (0.56) HDAC8HDAC6
SCHEMBL10247370 0.75 HDAC8 (0.56) HDAC8HDAC6
SCHEMBL444653 0.74 HDAC8 (0.64) HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 HDAC8 13/4885HDAC6 1/4885MTNR1A 1476/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 HDAC8 20/4885HDAC6 1/4885MTNR1A 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.